Komek, HalilCan, CananYilmaz, UgurAltindag, Serdar2024-04-242024-04-2420180914-71871864-6433https://doi.org/10.1007/s12149-018-1277-5https://hdl.handle.net/11468/14891ObjectiveTo determine the association of 68Ga-PSMA-I&T PET/CT SUV parameters with survival outcome in advanced prostate cancer patients.MethodsA total of 148 consecutive patients mean age: 69.37.8years with advanced prostate cancer who underwent 68Ga-PSMA-I&T PET/CT were included in this retrospective study. Data on previous treatments, serum PSA levels (ng/mL), 68Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded.ResultsMultivariate regression analysis revealed that Level 1 LN SUV/Liver SUV ratios>2.17 (OR 4.262; 95% CI 1.104-16.453, p=0.035), bone SUV>10.7(OR 23.650; 95% CI 4.056-137.888, p<0.001), bone SUV/spleen SUV ratio>1.842 (OR 25.324; 95% CI 4.204-152.552, p<0.001), highest SUVmax/liver SUV ratio>2.32 (OR 19.309; 95% CI 1.730-209.552, p=0.016) and highest SUVmax/spleen SUV ratio>1.842 (OR 22.354; 95% CI 2.637-189.493, p=0.004) were significant in the determination of increased mortality risk in advanced prostate cancer patients.Conclusion p id=Par4 Our findings, for the first time in literature, provided evidence on potential utility of tracer uptake (SUV) cut-off values on 68Ga-PSMA PET/CT in identification of the survival outcome of patients with metastatic disease and thereby in assisting in the selection of individualized therapeutic strategies tailored to the expected prognosis.eninfo:eu-repo/semantics/closedAccessProstate Cancer68ga-Psma-I&T PetCtMetastasisLymph NodeBoneSuvArticle328542552WOS:0004457326000053000675210.1007/s12149-018-1277-5Q3